Compositions, methods and kits for the reduction of protein aggregation are provided. Specifically, the disclosure provides a protein that is responsible for the resistance to polyglutamine aggregation, and provides compositions comprising an isolated peptide that is able to reduce aggregation, and methods and kits for the treatment of diseases associated with protein aggregation, particularly polyglutamine disease, including Huntington's disease. Further provided are the amino acid sequence of the isolated peptide.
